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in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-59. To the Editor: We are puzzled by the concluding statement of McMurray, 1 in his editorial accompanying the report on the ONTARGET trial, that "Because ARBs [angiotensin-receptor blockers] are more costly than ACE [angiotensin-converting-enzyme] inhibitors and have more side effects, their primary value is as an alternative for patients who cannot tolerate ACE inhibitors." The ONTARGET trial directly contradicts this statement. Although 621 patients permanently discontinued ramipril, only 438 patients permanently discontinued telmisartan. When hypotensive symptoms of an antihypertensive drug (an expected effect) are omitted, more than twice as many patients discontinued ramipril as discontinued telmisartan. Also, so-called hypotensive symptoms have little meaningful value unless the corresponding blood pressure is recorded. In addition, several randomized trials have shown that ARBs have fewer adverse effects than ACE inhibitors (Table 1) . Notably, in ONTARGET, angioedema, which can be fatal, was 2.5 times as common in patients receiving ramipril as in those receiving telmisartan. These findings clearly do not attest to the conclusion that ARBs have a greater number of adverse effects than ramipril, as stated by The editorialist replies: I referred to the only two trials that showed noninferiority of an ARB as compared with an ACE inhibitor and therefore permit a legitimate comparison of tolerability. 1 In the Valsartan in Acute Myocardial Infarction Trial (VALIANT), valsartan led to significantly more reductions in the dose of the study drug because of hypotension and renal dysfunction than did captopril. Treatment discontinuation because of hypotension was also significantly more common with valsartan (and discontinuation due to renal dysfunction was numerically more frequent with valsartan). As expected, cough was much less common with valsartan.
Only study-drug discontinuations were reported (as multiple episodes) in ONTARGET, but exactly the same pattern was observed. It is important to note that the net difference of 137 more discontinuations for any reason with ramipril reflected the balance of 267 fewer discontinuations because of cough with telmisartan, offset by other adverse effects that in my opinion may be more clinically significant (e.g., hypotension, for which there was a net excess of 80 cases with telmisartan).
